

# CITATION REPORT

List of articles citing

**Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes**

**DOI: 10.1111/jcpt.13226**

**Journal of Clinical Pharmacy and Therapeutics, 2020,  
45 Suppl 1, 61-72.**

**Source:** <https://exaly.com/paper-pdf/76155484/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	An overview of the once-weekly GLP-1 receptor agonists from the pharmacists perspective. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45 Suppl 1, 3-6	2.2	0
6	Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45 Suppl 1, 7-16	2.2	1
5	Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45 Suppl 1, 28-42	2.2	3
4	Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45 Suppl 1, 61-72	2.2	4
3	[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases]. <i>Kardiologiya</i> , <b>2021</b> , 61, 66-72	1.5	
2	Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. <b>2022</b> , 35, 440-451		0
1	Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence.		0